ImmunoCellular Therapeutics (FRA:KOL1) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2018)

View and export this data going back to . Start your Free Trial

What is ImmunoCellular Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. ImmunoCellular Therapeutics's long-term debt to total assests ratio for the quarter that ended in Jun. 2018 was 0.00.

ImmunoCellular Therapeutics's long-term debt to total assets ratio stayed the same from Jun. 2017 (0.00) to Jun. 2018 (0.00).

ImmunoCellular Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for ImmunoCellular Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunoCellular Therapeutics LT-Debt-to-Total-Asset Chart

ImmunoCellular Therapeutics Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

ImmunoCellular Therapeutics Quarterly Data
	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

ImmunoCellular Therapeutics LT-Debt-to-Total-Asset Calculation

ImmunoCellular Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2017 is calculated as

LT Debt to Total Assets (A: Dec. 2017 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2017 )	/	Total Assets (A: Dec. 2017 )
	=	0	/	5.923
	=

ImmunoCellular Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2018 is calculated as

LT Debt to Total Assets (Q: Jun. 2018 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2018 )	/	Total Assets (Q: Jun. 2018 )
	=	0	/	3.278
	=

ImmunoCellular Therapeutics (FRA:KOL1) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

ImmunoCellular Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of ImmunoCellular Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunoCellular Therapeutics (FRA:KOL1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoCellular Therapeutics Ltd (FRA:KOL1) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645

Website

https://www.eompharma.com

EOM Pharmaceutical Holdings Inc is focused on developing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases. Its product candidate includes dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147 is being studied to treat serious retinal diseases without the need for intraocular injection.

ImmunoCellular Therapeutics (FRA:KOL1) Headlines

No Headlines